Gene: Jmjd6 (jumonji domain containing 6)
Rattus norvegicus |
| Symbol: |
Jmjd6
|
| Name: |
jumonji domain containing 6
|
| Description: |
ENCODES a protein that exhibits histone demethylase activity (H3-R2 specific) (ortholog); histone demethylase activity (H4-R3 specific) (ortholog); identical protein binding (ortholog); INVOLVED IN apoptotic process (ortholog); blood vessel development (ortholog); cell surface receptor signaling pathway (ortholog); FOUND IN nucleolus (ortholog); nucleoplasm (ortholog); nucleus (ortholog); INTERACTS WITH 2,4-dinitrotoluene; dibutyl phthalate; nickel dichloride |
| Type: |
protein-coding
|
| RefSeq Status: |
VALIDATED
|
| Also known as: |
bifunctional arginine demethylase and lysyl-hydroxylase JMJD6; histone arginine demethylase JMJD6; jmjC domain-containing protein 6; jumonji domain-containing protein 6; LOC360665; lysyl-hydroxylase JMJD6; peptide-lysine 5-dioxygenase JMJD6; phosphatidylserine receptor; phosphatidylserine receptor (predicted); Ptdsr; ptdsr; Ptdsr_predicted
|
| Orthologs: |
Homo sapiens : JMJD6
(jumonji domain containing 6)
HGNC
Mus musculus : Jmjd6
(jumonji domain containing 6)
MGI
|
| Latest Assembly: |
RGSC Genome Assembly v3.4
|
| Position: |
| Map | Chr | Position | Strand | Source |
|---|
Rat Cytogenetic Map | 10 | q32.3 | | NCBI | RGSC Genome Assembly v5.0 | 10 | 105,440,305 - 105,446,356 | - | NCBI | RGSC Genome Assembly v3.4 | 10 | 106,942,942 - 106,948,652 | - | NCBI | Rat Celera Assembly | 10 | 100,609,595 - 100,615,642 | - | NCBI | Genome Assembly 3.1 | 10 | 106,957,446 - 106,963,156 | - | NCBI |
|
| Model |
|
 Gene-Chemical Interaction Annotations
| (S)-nicotine | multiple interactions | ISO | RGD:1313401 | 6480464 | [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; more ... | CTD | PMID:20230807 | | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | increases expression | ISO | RGD:1313401 | 6480464 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA | CTD | PMID:20230807 | | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | multiple interactions | ISO | RGD:1313401 | 6480464 | [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; more ... | CTD | PMID:20230807 | | 17beta-estradiol | affects expression | ISO | RGD:1313401 | 6480464 | Estradiol affects the expression of JMJD6 mRNA | CTD | PMID:15598610 | | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1313401 | 6480464 | Tetrachlorodibenzodioxin affects the expression of JMJD6 mRNA | CTD | PMID:21570461 | | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2,4-dinitrotoluene affects the expression of JMJD6 mRNA | CTD | PMID:21346803 | | aflatoxin B1 | increases expression | ISO | RGD:1313401 | 6480464 | Aflatoxin B1 results in increased expression of JMJD6 mRNA | CTD | PMID:19770486 | | arsenic atom | affects expression | ISO | RGD:1313400 | 6480464 | Arsenic affects the expression of JMJD6 mRNA | CTD | PMID:18414638 | | benzo[a]pyrene | multiple interactions | ISO | RGD:1313401 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in decreased expression of JMJD6 mRNA | CTD | PMID:21715664 | | cadmium dichloride | multiple interactions | ISO | RGD:1313401 | 6480464 | [Methylnitronitrosoguanidine co-treated with Cadmium Chloride] results in increased expression of JMJD6 mRNA | CTD | PMID:19840844 | | cisplatin | decreases expression | ISO | RGD:1313401 | 6480464 | Cisplatin results in decreased expression of JMJD6 mRNA | CTD | PMID:21151649 | | clofibrate | decreases expression | ISO | RGD:1313401 | 6480464 | Clofibrate results in decreased expression of JMJD6 mRNA | CTD | PMID:17585979 | | cobalt dichloride | increases expression | ISO | RGD:1313400 | 6480464 | cobaltous chloride results in increased expression of JMJD6 mRNA | CTD | PMID:19376846 PMID:19320972 | | cobalt dichloride | increases expression | ISO | RGD:1313400 | 6480464 | cobaltous chloride results in increased expression of JMJD6 mRNA | CTD | PMID:19320972 PMID:19376846 | | cyclosporin A | increases expression | ISO | RGD:1313400 | 6480464 | Cyclosporine results in increased expression of JMJD6 mRNA | CTD | PMID:20106945 | | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of JMJD6 mRNA | CTD | PMID:21266533 | | dioxygen | increases expression | ISO | RGD:1313401 | 6480464 | Oxygen deficiency results in increased expression of JMJD6 mRNA | CTD | PMID:20880076 | | formaldehyde | increases expression | ISO | RGD:1313400 | 6480464 | Formaldehyde results in increased expression of JMJD6 mRNA | CTD | PMID:20655997 | | lead diacetate | decreases expression | ISO | RGD:1313401 | 6480464 | lead acetate results in decreased expression of JMJD6 mRNA | CTD | PMID:21829687 | | N-methyl-N'-nitro-N-nitrosoguanidine | multiple interactions | ISO | RGD:1313401 | 6480464 | [Methylnitronitrosoguanidine co-treated with Cadmium Chloride] results in increased expression of JMJD6 mRNA | CTD | PMID:19840844 | | nickel dichloride | increases expression | EXP | | 6480464 | nickel chloride results in increased expression of JMJD6 mRNA | CTD | PMID:22110744 | | nickel sulfate | increases expression | ISO | RGD:1313401 | 6480464 | nickel sulfate results in increased expression of JMJD6 mRNA | CTD | PMID:16166746 | | ochratoxin A | increases expression | ISO | RGD:1313400 | 6480464 | ochratoxin A results in increased expression of JMJD6 mRNA | CTD | PMID:22124623 | | ochratoxin A | increases expression | EXP | | 6480464 | ochratoxin A results in increased expression of JMJD6 mRNA | CTD | PMID:22124623 | | pirinixic acid | multiple interactions | ISO | RGD:1313401 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of JMJD6 mRNA | CTD | PMID:19710929 | | piroxicam | increases expression | ISO | RGD:1313400 | 6480464 | Piroxicam results in increased expression of JMJD6 mRNA | CTD | PMID:21858171 | | tert-butyl hydroperoxide | increases expression | ISO | RGD:1313400 | 6480464 | tert-Butylhydroperoxide results in increased expression of JMJD6 mRNA | CTD | PMID:15336504 | | valproic acid | affects expression | ISO | RGD:1313401 | 6480464 | Valproic Acid affects the expression of JMJD6 mRNA | CTD | PMID:17292431 PMID:17963808 | | valproic acid | decreases expression | ISO | RGD:1313401 | 6480464 | Valproic Acid results in decreased expression of JMJD6 mRNA | CTD | PMID:19136453 | | valproic acid | affects expression | ISO | RGD:1313401 | 6480464 | Valproic Acid affects the expression of JMJD6 mRNA | CTD | PMID:17963808 PMID:17292431 | | zinc atom | multiple interactions | ISO | RGD:1313400 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of JMJD6 mRNA | CTD | PMID:18593933 | | zinc(0) | multiple interactions | ISO | RGD:1313400 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of JMJD6 mRNA | CTD | PMID:18593933 | |
 Gene Ontology Annotations
Biological Process
| apoptotic cell clearance | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3043930 | RGD | MGI:MGI:3042820 PMID:14715629 | | apoptotic cell clearance | NOT | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | apoptotic cell clearance | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3618422|PMID:15647754 | RGD | MGI:MGI:3618422 PMID:15647754 | | apoptotic process | | ISO | RGD:1313401 | 1624291 | MGI:MGI:1855743|PMID:10811223 | RGD | MGI:MGI:1855743 PMID:10811223 | | apoptotic process | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | biological_process | | ND | | 1598407 | 11/07: no relevant rat data | RGD | | | blood vessel development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3606737 PMID:15615595 | | cell surface receptor signaling pathway | | ISO | RGD:1313401 | 1624291 | MGI:MGI:1855743|PMID:10811223 | RGD | MGI:MGI:1855743 PMID:10811223 | | cell surface receptor signaling pathway | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | erythrocyte development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3043930 | RGD | MGI:MGI:3042820 PMID:14715629 | | erythrocyte development | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | erythrocyte development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | heart development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3606737 PMID:15615595 | | heart development | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | histone H3-R2 demethylation | | ISO | RGD:1313400 | 1624291 | PMID:17947579 | RGD | PMID:17947579 | | histone H4-R3 demethylation | | ISO | RGD:1313400 | 1624291 | PMID:17947579 | RGD | PMID:17947579 | | kidney development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | kidney development | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | lung development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:2686850 | RGD | MGI:MGI:2682078 PMID:14645847 | | lung development | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | lung development | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | macrophage activation | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | macrophage activation | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | mRNA processing | | IEA | UniProtKB-KW:KW-0507 | 1600115 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 | | peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine | | ISO | RGD:1313400 | 1624291 | PMID:19574390 | RGD | PMID:19574390 | | peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine | | ISS | UniProtKB:Q6NYC1 | 1600115 | GO_REF:0000024 | UniProtKB | GO_REF:0000024 | | recognition of apoptotic cell | | ISO | RGD:1313401 | 1624291 | MGI:MGI:2686850 | RGD | MGI:MGI:2682078 PMID:14645847 | | recognition of apoptotic cell | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | regulation of mRNA splicing, via spliceosome | | ISO | RGD:1313401 | 1624291 | MGI:MGI:4940413|PMID:21300889 | RGD | MGI:MGI:4940413 PMID:21300889 | | regulation of mRNA splicing, via spliceosome | | ISS | UniProtKB:Q6NYC1 | 1600115 | GO_REF:0000024 | UniProtKB | GO_REF:0000024 | | regulation of mRNA splicing, via spliceosome | | ISO | RGD:1313400 | 1624291 | PMID:19574390 | RGD | PMID:19574390 | | regulation of transcription, DNA-dependent | | IEA | UniProtKB-KW:KW-0805 | 1600115 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 | | retina development in camera-type eye | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3580706 | RGD | MGI:MGI:3580691 PMID:15345036 | | retina development in camera-type eye | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | RNA splicing | | IEA | UniProtKB-KW:KW-0508 | 1600115 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 | | sprouting angiogenesis | | ISO | RGD:1313401 | 1624291 | MGI:MGI:4940413|PMID:21300889 | RGD | MGI:MGI:4940413 PMID:21300889 | | sprouting angiogenesis | | ISS | UniProtKB:Q9ERI5 | 1600115 | GO_REF:0000024 | UniProtKB | GO_REF:0000024 | | T cell differentiation in thymus | | ISO | RGD:1313401 | 1624291 | MGI:MGI:3043930 | RGD | MGI:MGI:3042820 PMID:14715629 | | T cell differentiation in thymus | | IEA | Ensembl:ENSMUSP00000047570 | 1600115 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 | | transcription, DNA-dependent | | IEA | UniProtKB-KW:KW-0804 | 1600115 | GO_REF:0000037 | UniProtKB | GO_REF:0000037 | |
| 2303118 | Mamtr7 | Mammary tumor resistance QTL 7 | | .003 | Mammary tumor resistance | | 10 | 9762188 | 108776963 | Rat |
| 2316949 | Gluco60 | Glucose level QTL 60 | 3.7 | | Glucose level | postprandial | 10 | 14721135 | 154166503 | Rat |
| 631268 | Cia21 | Collagen induced arthritis QTL 21 | 3.1 | | Joint/bone inflammation | arthritis severity | 10 | 14721135 | 159833317 | Rat |
| 61354 | Pia10 | Pristane induced arthritis QTL 10 | | .01 | Joint/bone inflammation | pristane induced | 10 | 24006429 | 160657542 | Rat |
| 631267 | Cia20 | Collagen induced arthritis QTL 20 | 3.2 | | Joint/bone inflammation | arthritis severity | 10 | 24006429 | 160657542 | Rat |
| 61325 | Aia5 | Adjuvant induced arthritis QTL 5 | | .01 | Joint/bone inflammation | arthritis severity | 10 | 24006429 | 160657542 | Rat |
| 631270 | Cia23 | Collagen induced arthritis QTL 23 | 3.9 | | Joint/bone inflammation | arthritis severity | 10 | 41339689 | 152260081 | Rat |
| 631269 | Cia22 | Collagen induced arthritis QTL 22 | 8.9 | | Joint/bone inflammation | arthritis severity | 10 | 41339689 | 152260081 | Rat |
| 1298078 | Stresp5 | Stress response QTL 5 | 2.99 | .00025 | Hormone level | corticosterone | 10 | 43458380 | 108776963 | Rat |
| 2293698 | Bss43 | Bone structure and strength QTL 43 | 5.33 | .0001 | Bone structure | | 10 | 62984501 | 107984501 | Rat |
| 1576308 | Schws1 | Schwannoma susceptibility QTL 1 | | .0041 | Neural tumor susceptibility | tumor incidence, length of survival time | 10 | 63816942 | 108816942 | Rat |
| 2298548 | Neuinf7 | Neuroinflammation QTL 7 | 2.2 | | Neuroinflammation | | 10 | 65668446 | 132729388 | Rat |
| 1358915 | Stresp7 | Stress response QTL 7 | 3.52 | | Hormone level | norepinephrine | 10 | 68955627 | 113955627 | Rat |
| 2317029 | Aia19 | Adjuvant induced arthritis QTL 19 | 2.98 | | Joint/bone inflammation | adjuvant induced | 10 | 70229781 | 115229781 | Rat |
| 2317039 | Aia6 | Adjuvant induced arthritis QTL 6 | 4.31 | | Joint/bone inflammation | adjuvant induced | 10 | 70229781 | 115229781 | Rat |
| 61396 | Bp9 | Blood pressure QTL 9 | 4.8 | .0001 | Blood pressure | salt-loaded systolic | 10 | 72871396 | 117871396 | Rat |
| 2293646 | Bss25 | Bone structure and strength QTL 25 | 10.96 | .0001 | Bone structure | | 10 | 74167134 | 119167134 | Rat |
| 2293663 | Bss33 | Bone structure and strength QTL 33 | 9.34 | .0001 | Bone structure | | 10 | 74167134 | 119167134 | Rat |
| 2300172 | Bmd57 | Bone mineral density QTL 57 | 9.8 | .0001 | Bone mineral density | | 10 | 74167134 | 119167134 | Rat |
| 6893366 | Bw106 | Body weight QTL 106 | .3 | .47 | Body weight | | 10 | 74652410 | 119652410 | Rat |
| 70193 | Mcs7 | Mammary carcinoma susceptibility QTL 7 | 2.38 | | Mammary tumor susceptibility | | 10 | 76698917 | 121698917 | Rat |
| 1354641 | Bvd2 | Brain ventricular dilatation QTL 2 | 6.36 | .001 | Head/brain development | brain ventricular dilatation | 10 | 79981838 | 124981838 | Rat |
| 4889492 | Pancm2 | Pancreatic morphology QTL 2 | 3.2 | | Pancreatic morphology | | 10 | 81350126 | 126350126 | Rat |
| 2303589 | Bw87 | Body weight QTL 87 | 2 | | Body weight | | 10 | 86057484 | 131057484 | Rat |
| 2317754 | Glom25 | Glomerulus QTL 25 | 3.5 | | Renal pathology | urine protein level | 10 | 86810917 | 131810917 | Rat |
| 1600367 | Mcs15 | Mammary carcinoma susceptibility QTL 15 | 4.5 | | Mammary tumor susceptibility | | 10 | 89575059 | 108822775 | Rat |
| 631538 | Oia5 | Oil induced arthritis QTL 5 | | | Joint/bone inflammation | arthritis susceptibility | 10 | 91168332 | 136168332 | Rat |
| 61363 | Oia3 | Oil induced arthritis QTL 3 | | .001 | Joint/bone inflammation | oil induced | 10 | 91455572 | 136455572 | Rat |
| 1300137 | Bp186 | Blood pressure QTL 186 | 3.57 | | Blood pressure | salt-loaded time series calculation | 10 | 95066219 | 140066219 | Rat |
| 1558652 | Bw57 | Body weight QTL 57 | 4.2 | .0008 | Body weight | | 10 | 95361338 | 140361338 | Rat |
| 61436 | Cia5 | Collagen induced arthritis QTL 5 | 4.9 | | Joint/bone inflammation | type II collagen induced | 10 | 95692240 | 140692240 | Rat |
| 1302404 | Cia27 | Collagen induced arthritis QTL 27 | | | Joint/bone inflammation | type II collagen induced | 10 | 95695048 | 111406914 | Rat |
| 1576307 | Cia28 | Collagen induced arthritis QTL 28 | | | Joint/bone inflammation | type II collagen-induced | 10 | 100633512 | 145633512 | Rat |
| 1576313 | Pia25 | Pristane induced arthritis QTL 25 | | | Joint/bone inflammation | pristane induced | 10 | 100633512 | 145633512 | Rat |
| 1578663 | Bss18 | Bone structure and strength QTL 18 | 3.6 | | Bone structure | femoral neck width | 10 | 101222719 | 146222719 | Rat |
| 1578672 | Bmd16 | Bone mineral density QTL 16 | 6.2 | | Bone mineral density | femoral neck cortical vBMD | 10 | 101222719 | 146222719 | Rat |
| 631539 | Oia6 | Oil induced arthritis QTL 6 | | | Joint/bone inflammation | arthritis susceptibility | 10 | 101532360 | 108776963 | Rat |
| 1357340 | Bp250 | Blood pressure QTL 250 | | .0001 | Blood pressure | | 10 | 101848470 | 146848470 | Rat |
| 2312662 | Slep8 | Serum leptin concentration QTL 8 | | .05 | Hormone level | leptin | 10 | 106422174 | 107033716 | Rat |
| 2312668 | Scl65 | Serum cholesterol level QTL 65 | | .001 | Lipid level | serum cholesterol | 10 | 106422174 | 107033716 | Rat |
| 2312672 | Insul15 | Insulin level QTL 15 | | .01 | Insulin level | serum | 10 | 106422174 | 107033716 | Rat |